France Addiction Therapeutics Market Analysis

France Addiction Therapeutics Market Executive Summary

France addiction therapeutics market was valued at $278 Mn in 2022 and is estimated to reach $438 Mn in 2030, exhibiting a CAGR of 5.9% during the forecast period.

Addiction therapy uses a variety of techniques, interventions, and approaches to treat and prevent addiction. Its main goal is to reduce or eliminate the use of substances, especially drugs and alcohol, and to support those struggling with co-morbidities and addiction. Effective addiction treatment usually requires a customized, comprehensive strategy that takes into account each patient's unique situation, drug use history, comorbidities, and social networks. Two commonly prescribed medications used in the ongoing treatment of opioid use disorder addiction are methadone and buprenorphine. Other medications that are approved for the treatment of substance use disorders include naltrexone, acamprosate, and disulfiram; however, these may not be initiated until after detox.

As of January 1, 2022, 77.5% of prisoners in France were convicted of crime, with 13.5% of these convictions having a connection to drug-related offenses. Cannabis is still the most commonly used illegal substance among those aged 18 to 64, making up 46% of users and an estimated 18 million of them having tried it. 11.3% of adults had used cannabis in the previous year. For recent users aged 18–64, a high risk of problematic cannabis use was at 25%, which is 2.3% of the French population in 2017. Additionally, 1.3% of adults aged 18–64 use synthetic cannabinoids, which are comparable to heroin or amphetamines. Despite the stabilization of cannabis consumption between 2017 and 2020 in different age groups, the trend continues at a consistently high level, indicating a dynamic landscape due to the different sources of supply in France, including local cannabis cultivation and the emerging resin market. The consumption of substances has increased significantly and rapidly across Europe. About 3.5 Mn people have been identified as regular users, 600,000 of whom are in France. This figure represents a significant increase compared to the 400,000 registered users in 2010, which means that France is one of the countries most affected by this growing trend of drug use.

Research conducted at the INSERM (French National Institute of Health and Medical Research) is investigating the possibility of treating opioid addiction with a combined strategy that combines buprenorphine with mindfulness and meditation. Also, researchers at the University of Bordeaux are looking at how well the antioxidant N-acetylcysteine works to treat cocaine addiction. Preliminary research suggests that it may lessen cravings and improve relapse prevention in cocaine addiction sufferers.

Market Dynamics

Market Growth Drivers

Rising Substance Use Rates: Increasing rates of substance use, including cannabis and other illegal drugs, increase the need for addiction treatment in a larger population. Substance use disorders increase the need for effective treatments and accelerate the growth of the addiction treatment market.

Awareness and Education Initiatives: The addiction treatment market is growing as a result of ongoing campaigns, educational programs, and governmental and non-governmental initiatives aimed at reducing stigma, supporting early intervention, and encouraging help-seeking behavior.

Government Initiatives and Support: Support from government agencies through policies, initiatives, and strategic plans aimed at combating drugs and addiction significantly influences the growth of the addiction therapeutics market. The Centres de Soins d'Accueil et de Prévention en Addictologie (CSAPA), or "Care, Support, and Prevention Centres in Addiction," are a well-established network run by the French government. Growing investments in addiction treatment programs and healthcare infrastructure are driving the expansion of the addiction treatment market.

Market Restraints

Cost of Treatment: Affordability and reimbursement issues related to addiction treatment can impede access. High care costs combined with inadequate insurance coverage can limit an individual’s ability to obtain necessary drugs or treatments, which will affect market growth.

Treatment Adherence and Compliance: Inadequate patient compliance with recommended dosage schedules or unfinished treatment programs can reduce the efficacy of medications used to treat addiction, which may have an adverse effect on the market's potential for growth.

Stigma and Perception: Stigma and societal attitudes toward addiction can prevent people from seeking treatment. Misconceptions or societal prejudices about addiction can prevent affected individuals from acknowledging their illness or seeking appropriate treatment options. This stigma associated with substance abuse restricts the market's potential for expansion.

Healthcare Policies and Regulatory Landscape

The French National Agency for Medicines and Health (ANSM - Agence Nationale de Securité du Médicament et des Produits de Santé) controls the approval, licensing, and supervision of drugs used in the treatment of addiction and strictly monitors safety, quality, and effectiveness before entering the market. It regulates the entire life cycle of these medicines and ensures the fulfilment of strict criteria. Specific guidelines dictate the prescribing, dispensing, and administration of addiction medications and often require special training or certification for health care professionals who administer controlled substances for addiction treatment. These measures aim to ensure the appropriate use of these drugs by reducing the risk of abuse or misuse in the health system. The French National Agency for the Safety of Medicines and Health Products (ANSM) has a complex and stringent licensing and approval process for addiction drugs. It entails thorough documentation that includes safety profiles, clinical trial data, manufacturing specifics, and pharmacological qualities. It is essential to abide by the changing regulatory criteria set forth by ANSM for drug research, production, and quality control. Before approving a medicine, ANSM does extensive studies and expert assessments that frequently necessitate several reviews in order to guarantee the drug's quality, safety, and efficacy. It is necessary to conduct continuous post-market surveillance for safety and efficacy, which necessitates continuous compliance and prompt reporting of any new problems. In order to achieve the high safety and efficacy requirements established by ANSM, navigating this process requires a significant investment of time, money, and compliance with stringent regulatory criteria.

Competitive Landscape

Key Players

• Indivior
• Reckitt Benckiser Pharmaceuticals
• Sanofi
• Ethypharm
• Mundipharma
• Bioprojet Pharma
• GlaxoSmithKline
• Pfizer
• Novartis
• Merck KGaA